Please login to the form below

Not currently logged in

ADA presents diabetes studies

Studies involving diabetes products from several pharma companies, including Sanofi, Novo Nordisk and Bristol-Myers Squibb, have been presented at the American Diabetes Association's Scientific Sessions

Studies involving diabetes products from several pharma companies, including Sanofi, Novo Nordisk and Bristol-Myers Squibb, have been presented at the American Diabetes Association's Scientific Sessions.

Among the developments to be announced at the meeting in San Diego, US, were the results of Sanofi's 'All to Target' trial evaluating two separate regimens with different doses of Lantus and Apidra versus premixed insulin (Novolog).

The trial showed the combination of Lantus and Apidra led to larger proportions of patients achieving target glycated haemoglobin  with statistically lower rates of hypoglycemia and greater fasting plasma glucose reductions, although superiority versus premixed insulin was not achieved.

Speaking to PMLiVE, Pierre Chancel, senior vice president global diabetes, Sanofi, commented on the "very interesting" results, citing greater patient satisfaction with the Lantus/Apidra treatments over the premixed insulin as one of the key findings from the study.

Chancel described diabetes care as a complex job with self-management and adherence as important parts of the process, with the "fear" of hypoglaceamia greater in those patients using the premixed insulin solution.

The simplicity of treatment was also important for Chancel, with ongoing efforts to empower patients to manage their condition in the easiest way possible.

Data on investigational compound Lyxumia (lixisenatide) was also presented by Sanofi, with the once-daily GLP-1 receptor agonist found to have non-inferiority head-to-head phase III trial versus exenatide twice daily.

Bristol-Myers Squibb (BMS) and AstraZeneca (AZ) also presented data at the event, announcing the results of a phase III clinical study examining the investigational compound dapagliflozin at 5mg or 10mg plus metformin extended-release (XR).

Previously-untreated adults with type 2 diabetes who had high baseline blood sugar levels demonstrated reduced blood sugar levels compared to dapagliflozin or metformin XR alone plus placebo when taking dapagliflozin, with no major hypoglycaemia-related events during the study.

Novo Nordisk's investigational ultra-long-acting insulin degludec was also shown to have reduced hypoglycaemia and improved long-term control in patients with type 1 and type 2 diabetes in a 52-week phase III trial.

The sessions come in the same week as The Lancet has published a study from Harvard and Imperial College that the number of adults with diabetes in the world has more than doubled since 1980.

It is thought numbers of people with the condition have risen from 153 million to 347 million, with the authors putting the rise down to greater life expectancy and rising levels of obesity.

Diabetes UK and Newcastle University announced last week results of a study that has the potential to 'reverse' the condition in people with type 2 diabetes if patients undergo an extremely low calorie diet.

27th June 2011


PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...